CCR2 on CD14(+)CD16(+) monocytes is a biomarker of HIV-associated neurocognitive disorders

Antzeko izenburuak

• JAM-A and ALCAM are therapeutic targets to inhibit diapedesis across the BBB of CD14(+)CD16(+) monocytes in HIV-infected individuals
  nork: Williams, Dionna W., et al.
  Argitaratua: (2015)
• CCR2 on peripheral blood CD14(+)CD16(+) monocytes correlates with neuronal damage, HIV-associated neurocognitive disorders, and peripheral HIV DNA: reseeding of CNS reservoirs?
  nork: Veenstra, Mike, et al.
  Argitaratua: (2018)
• Frontline Science: CXCR7 mediates CD14(+)CD16(+) monocyte transmigration across the blood brain barrier: a potential therapeutic target for NeuroAIDS
  nork: Veenstra, Mike, et al.
  Argitaratua: (2017)
• Dopamine Increases CD14(+)CD16(+) Monocyte Transmigration Across the Blood Brain Barrier: Implications for Substance Abuse and HIV Neuropathogenesis
  nork: Calderon, Tina M., et al.
  Argitaratua: (2017)
• Mechanisms of HIV Entry into the CNS: Increased Sensitivity of HIV Infected CD14(+)CD16(+) Monocytes to CCL2 and Key Roles of CCR2, JAM-A, and ALCAM in Diapedesis
  nork: Williams, Dionna W., et al.
  Argitaratua: (2013)